financial guidance

The company posted a 3 percent increase in molecular diagnostics sales at constant exchange rates, and a 3 percent decline in instrument sales.

The company, which beat Wall Street expectations on the top and bottom lines, said completed Cologuard test volume rose 150 percent over Q1 2016.

The company reported $4.77 billion in first quarter revenues, driven by growth in all of its business segments.

The company said revenues for the quarter and full-year 2016 included sales of Olerup HLA typing products, which CareDx got through its acquisition of Allenex.

The company beat Wall Street analysts' expectations for sales and earnings per share during the quarter.

The company also said it has closed a new $25 million debt facility, and will use the proceeds to retire outstanding debt and bolster the launch of AlloSure.

The company said it completed 82,000 Cologuard tests during the quarter, a 114 percent growth in test volume during the three-month period.

The firm's full-year 2016 revenues fell 9 percent, also on lower instrument sales.

The company said the divestiture of its medical imaging business in the fourth quarter reduced revenues to below previous guidance.  

For full year 2016, the company reported 8 percent revenue growth and net income of $2.02 billion.